Taysha Gene Therapies, Inc. Board of Directors

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Mr. Sean McAuliffe

Mr. Sean McAuliffe

Chief Business Officer

Dr. Sukumar Nagendran M.D.

Dr. Sukumar Nagendran M.D.

President, Head of Research & Development and Director

Mr. Frederick Porter Ph.D.

Mr. Frederick Porter Ph.D.

Chief of Staff & Technical Operations Officer

Ms. Emily McGinnis M.P.H.

Ms. Emily McGinnis M.P.H.

Chief Patient & External Affairs Officer and Endpoint & Outcome Development Lead

Dr. Steven Gray Ph.D.

Dr. Steven Gray Ph.D.

Chief Scientific Advisor of UT Southwestern Gene Therapy Program

Mr. Kamran Alam CPA, M.B.A.

Mr. Kamran Alam CPA, M.B.A.

CFO & Corporate Secretary

Hayleigh Collins

Hayleigh Collins

Director of Corporate Communications & Investor Relations

Berge Minassian M.D.

Berge Minassian M.D.

Chief Medical Advisor of UT Southwestern Gene Therapy Program

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.